Mainz Biomed Reports Topline Results From Pooled Study Evaluating Novel MRNA Biomarkers And Proprietary AI Algorithm For Integration Into Pivotal FDA PMA Clinical Trial For Next Generation Colorectal Cancer Diagnostic
Mainz Biomed Reports Topline Results From Pooled Study Evaluating Novel MRNA Biomarkers And Proprietary AI Algorithm For Integration Into Pivotal FDA PMA Clinical Trial For Next Generation Colorectal Cancer Diagnostic
Mainz Biomed报告了评估新型MRNA生物标志物和专有人工智能算法的合并研究的主要结果，这些研究旨在整合到下一代结直肠癌诊断的关键FDA PMA临床试验
-
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%
-
690 subjects analyzed including previously unexamined and reported patients from Company's ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm
-
The power to determine advanced adenoma, lesions in a pre-cancerous stage, can change the entire CRC diagnostic field, by treating the patient before the polyps can progress to cancer
-
The power to determine advanced adenoma, lesions in a pre-cancerous stage, can change the entire CRC diagnostic field, by treating the patient before the polyps can progress to cancer
- 开创性的顶线结果显示，对结直肠癌的灵敏度为92％，特异性为90％，对晚期腺瘤的灵敏度为82％，处于同类最佳水平
- 分析了690名受试者，包括公司利用mRNA生物标志物、FIT测试和专有的人工智能算法进行的ColoFuture和Early DETECT研究中以前未经检查和报告的患者
- 通过在息肉发展为癌症之前对患者进行治疗，确定晚期腺瘤（癌前阶段的病变）的能力可以改变整个结直肠癌的诊断领域
- 通过在息肉发展为癌症之前对患者进行治疗，确定晚期腺瘤（癌前阶段的病变）的能力可以改变整个结直肠癌的诊断领域